Howard Jeffrey T, Walick Kristina S, Rivera Jessica C
*US Army Institute of Surgical Research, San Antonio ‡Department of Orthopaedics and Rehabilitation, San Antonio Military Medical Center, Fort Sam Houston, TX †Evans Army Community Hospital, Department of Orthopaedics, Fort Carson, CO.
J Pediatr Orthop. 2017 Jul/Aug;37(5):348-354. doi: 10.1097/BPO.0000000000000651.
The US Centers for Disease Control and Prevention estimate that 3.5 million children use psychotropic drugs for attention-deficit hyperactivity disorder (ADHD). With an increase in use of these types of drugs, thorough understanding of their potential side effects on the growing skeleton is needed. The purpose of this study was to determine whether there is an association between use of ADHD medication and diminished bone health.
Three waves of the National Health and Nutrition Examination Survey public-use data set, collected from 2005 through 2010, were compiled for this study (N=5315). Bone health was measured using dual-energy x-ray absorptiometry scans, which were performed for participants aged 8 to 17 years to determine bone mineral density (BMD) for 3 regions: (1) total femur; (2) femoral neck; and (3) lumbar. Use of ADHD medications was determined by self-reported responses to questions regarding prescription drug use, which were answered by either the respondent or the respondent's parent or guardian. Multiple statistical techniques were used to produce estimates of association between ADHD medication use and z score age and sex standardized BMD measures, including survey adjusted univariate, survey adjusted multiple linear regression, and generalized estimating equations with a propensity-matched subsample (N=1967). Multivariate models adjusted for covariates including time period, age, sex, race/ethnicity, family income to poverty ratio, and total number of prescription medications.
Conservative estimates of the difference in standardized BMD measures between the ADHD medication group and the nonmedicated group range from -0.4855 (±0.27; P<0.001) for total femoral, -0.4671 (±0.27; P<0.001) for femoral neck, and -0.3947 (±0.29; P<0.01) for lumbar. Significantly more children on ADHD medications versus match subjects on no medication had BMDs with in osteopenic range (38.3% vs. 21.6%, P<0.01).
The findings suggest that there are real and nontrivial differences in BMD for children and adolescents taking ADHD medications, as compared with similar children not taking any prescription medications. Prescribing physicians and parents should be aware of potential bone health risks associated with these medications.
Level III-case-control study.
美国疾病控制与预防中心估计,有350万儿童使用精神类药物治疗注意力缺陷多动障碍(ADHD)。随着这类药物使用的增加,需要深入了解其对正在生长的骨骼的潜在副作用。本研究的目的是确定ADHD药物的使用与骨骼健康受损之间是否存在关联。
本研究汇编了2005年至2010年收集的三轮美国国家健康与营养检查调查公共数据集(N = 5315)。使用双能X线吸收测定扫描来测量骨骼健康状况,对8至17岁的参与者进行扫描,以确定三个区域的骨矿物质密度(BMD):(1)全股骨;(2)股骨颈;(3)腰椎。ADHD药物的使用通过对有关处方药使用问题的自我报告回答来确定,这些问题由受访者或其父母或监护人回答。使用多种统计技术来估计ADHD药物使用与z评分年龄和性别标准化BMD测量值之间的关联,包括调查调整单变量分析、调查调整多元线性回归以及倾向匹配子样本(N = 1967)的广义估计方程。多变量模型对协变量进行了调整,包括时间段、年龄、性别、种族/族裔、家庭收入与贫困率以及处方药总数。
ADHD药物治疗组与未用药组之间标准化BMD测量值差异的保守估计范围为:全股骨为 -0.4855(±0.27;P < 0.001),股骨颈为 -0.4671(±0.27;P < 0.001),腰椎为 -0.3947(±0.29;P < 0.01)。与未用药的匹配受试者相比,服用ADHD药物的儿童中骨密度处于骨质减少范围内的明显更多(38.3% 对 21.6%,P < 0.01)。
研究结果表明,与未服用任何处方药的类似儿童相比,服用ADHD药物的儿童和青少年在骨密度方面存在真实且显著的差异。开处方的医生和家长应意识到这些药物相关的潜在骨骼健康风险。
III级——病例对照研究。